This systematic review and meta-analysis assessed the efficacy and safety of sacubitril/valsartan (S/V) compared to ACEI or ARB in heart failure (HF) patients. Eleven RCTs (n=18766) were included. S/V reduced HF hospitalizations by 20%, CV mortality by 14%, and all-cause mortality by 11% compared to ACEI or ARB. S/V also improved biomarkers and renal function, but increased hypotension. Angioedema and hyperkalaemia events were similar between groups.
Publisher
Archives of Medical Science
Published On
May 14, 2023
Authors
Adrian V Hernandez, Vinay Pasupuleti, Nancy Scarpelli, Jack Malespini, Maciej Banach, Agata M Bielecka-Dabrowa
Tags
sacubitril/valsartan
heart failure
meta-analysis
ACEI
ARB
mortality
hospitalizations
Related Publications
Explore these studies to deepen your understanding of the subject.
